Table 2

Multivariate overall survival analysis on subgroup patients with ipilimumab week 7

	HR	Lower 95% CI	Upper 95% CI	P value
(A) Ipilimumab levels as a continuous variable
Multivariable analysis 1 (n=36, events=30)
Log_10 CXCL11 pretreatment	3.44	1.02	11.57	0.046
Sex
Female	Reference
Male	0.8	0.37	1.73	0.574
Age	0.99	0.95	1.02	0.483
ECOG
0	Reference
1–2	1.56	0.63	3.89	0.335
Prior Immunotherapy
No	Reference
Yes	0.66	0.29	1.48	0.314
Log_10 ipi week 7	0.26	0.04	1.6	0.148
(B) Ipilimumab levels as a categorical variable
Multivariable analysis 2 (n=36, events=30)
Log_10 CXCL11 pretreatment	2.79	0.82	9.55	0.102
Sex
Female	Reference
Male	0.73	0.33	1.61	0.438
Age	0.98	0.95	1.02	0.383
ECOG
0	Reference
1–2	1.29	0.52	3.17	0.583
Prior immunotherapy
No	Reference
Yes	0.52	0.22	1.22	0.133
ipi week 7 (median cut-off)
≤16.30 (mg/mL)	Reference
>16.30	0.31	0.11	0.84	0.022